| Filed On | Filing |
|---|---|
| 27 Feb 2026 |
8-K: Termination of a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +5 more
SECTION 1. Registered Office. The registered office of Avidity Biosciences, Inc. (the “Corporation”) shall be established and maintained at the office of Corporation Service Company, in the City of Wilmington, in the County of New Castle... |
| 26 Feb 2026 |
8-K: Submission of Matters to a Vote of Security Holders
At a special meeting of stockholders of Avidity Biosciences, Inc. (“Avidity” or the “Company”) held virtually via live webcast on February 26, 2026 (the “Special Meeting”), the Company’s stockholders voted in favor of the proposals ident... |
| 23 Feb 2026 |
8-K: Other Events
Press Release: Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders |
| 03 Feb 2026 |
8-K: Regulation FD Disclosure; Other Events
Avidity Biosciences Announces Expected Record Date for Spin-Off |
| 18 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
As you may be aware, Avidity Biosciences, Inc. (the “Company”) has entered into a definitive agreement pursuant to which the Company will be acquired by Novartis AG (the “Merger” and, such agreement, the “Merger Agreement”). This letter ... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology programs into a new public company ("SpinCo") |
| 27 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Form of Certificate of Incorporation of the Surviving Corporation |
| 14 Oct 2025 |
8-K: Other Events
On October 13, 2025, Avidity Biosciences, Inc. ("Avidity") announced that based on a pre-Biologics License Application ("BLA") meeting with the U.S. Food and Drug Administration ("FDA") regarding Avidity's planned BLA submission for del-... |
| 12 Sep 2025 |
8-K: Other Events
1. INTRODUCTORY. Avidity Biosciences, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the “Underwriters,” or, each, an “Unde... |
| 10 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure +1 more
1 September 10, 2025 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Redefining the Treatment of Duchenne Muscular Dystrophy (DMD) Del-zota EXPLORE44-OLE Topline and Functional Data Exhibit 99.1 |
| 07 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition
Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE™ trial, and initiated global confirmatory Phase 3 study |
| 23 Jul 2025 |
8-K: Other Events
On July 23, 2025, Avidity Biosciences, Inc. ("Avidity") announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to delpacibart zotadirsen ("del-zota") for the treatment of Duchenne muscular dyst... |
| 10 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Avidity Biosciences, Inc., a Delaware corporation (the "Company"), held its 2025 Annual Meeting of Stockholders (the "2025 Annual Meeting") on June 10, 2025. The following is a brief description of each matter voted upon at the 2025 Annu... |
| 09 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
June 9, 2025 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Series Delivering for People Living with Facioscapulohumeral Muscular Dystrophy (FSHD) Exhibit 99.1 |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDETM trial in the second quarter |
| 29 Apr 2025 |
8-K: Changes in Registrant's Certifying Accountant
April 28, 2025 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on April 25, 2025, to be filed by Avidity ... |
| 25 Mar 2025 |
8-K: Other Events
On March 19, 2025, Avidity Biosciences, Inc. (the "Company") entered into that certain First Amendment to Sublease Agreement (the "Amendment"), by and between the Company and Turning Point Therapeutics, Inc. ("Sublandlord"), which amends... |
| 17 Mar 2025 |
8-K: Regulation FD Disclosure; Other Events
1 March 17, 2025 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Transforming Duchenne Muscular Dystrophy (DMD) Del-zota EXPLORE44® Phase 1/2 Topline Data |
| 27 Feb 2025 |
8-K: Results of Operations and Financial Condition
Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025 |
| 08 Jan 2025 |
8-K: Other Events
On January 8, 2025, Avidity Biosciences, Inc. ("Avidity" or the "Company") announced planned clinical and regulatory events for 2025. |
Loading...